Summit Therapeutics Flags Going Concern Risk Over Cash Needs - Summit Therapeutics (NASDAQ:SMMT)

Summit Therapeutics Inc.

(NASDAQ:SMMT) on Thursday reported an adjusted loss of 19 cents, better than the consensus loss of 28 cents per share.

Aggregate cash and cash equivalents and short-term investments were $690.7 million.

Company Raises Capital But Says More Funding Will Be Needed During the second quarter of 2026, the company raised $230.8 million in gross proceeds through its ATM facility.

Subsequent to June 2026, the company raised an additional $68.4 million in gross proceeds through its ATM facility.